Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,531 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Smallpox
Interventions: IMVAMUNE; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 56 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Orlando, Florida • Iowa City, Iowa • Lexington, Kentucky + 1 more

Conditions: Iron Deficiency
Interventions: Iron-dextran, Saline, Blood Donation, 24-hour PTR; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: ipratropium; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Migraine
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 8 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Restless Leg Syndrome
Interventions: incobotulinumtoxinA, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pain
Interventions: Acetaminophen, Bupivacain, Saline; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Trauma Injury
Interventions: Prothrombin Complex Concentrate, Human, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 2 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Healthy
Interventions: RVP-001, Placebo; Drug
Lead sponsor: Reveal Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Substance Use Disorders, Substance Use, Methamphetamine Abuse
Interventions: Ketamine Hydrochloride, Midazolam Hydrochloride; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more

Conditions: Lung Transplant; Complications, Mechanical, Lung Transplant; Complications, Bleeding, Hemoptysis
Interventions: Topical epinephrine, Placebos; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease
Interventions: LY3113593, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more

Conditions: Renal Colic
Interventions: Lidocaine, Ketorolac; Drug
Lead sponsor: The Brooklyn Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: COVID-19, SARS-CoV-2
Interventions: VYD222 (pemivibart), Normal saline; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Fullerton, California • Long Beach, California • Rolling Hills Estates, California + 15 more

Conditions: Acute Pain
Interventions: IV acetaminophen, IV placebo, hydromorphone; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 64 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions: pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF; Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Orlando, Florida • Durham, North Carolina

Conditions: Diabetes
Interventions: Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Kidney Injury
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Le Bonheur Children's Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Peripheral Arterial Disease
Interventions: Angiotensin 1-7, Saline; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: ketamine, IV Saline, ECT, Muscle Relaxant, Anesthetic Agents; Drug · Other · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Torticollis, Dystonia
Interventions: CBT; Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: SARS CoV-2
Interventions: Human Amniotic Fluid; Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions: Phage Therapy, Placebo; Drug · Other
Lead sponsor: Barbara Trautner; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: St Louis, Missouri • Houston, Texas

Conditions: Obesity
Interventions: benzocaine, placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 20 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation

Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

Vital Capacity in Ultrasound Guided Serratus Plane Block in ED Patients With Multiple Rib Fractures

Prehospital Kcentra for Hemorrhagic Shock

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

Ketamine for Methamphetamine Use Disorder

Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies

A Study of LY3113593 in Participants With Chronic Kidney Disease

Lidocaine vs Ketorolac for Management of Renal Colic in the Emergency Department

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus

Preventing Acute Kidney Injury (AKI) in Pediatric Patients

Angiotensin-(1-7) in Peripheral Arterial Disease

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

OnabotulinumtoxinA in the Management of Psychogenic Dystonia

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans